Fractionation technique and biochemical properties of IV Ig;Technique de fractionnement et proprietes biochimiques des immunoglobulines intraveineuses (IgIV)

Sang Thrombose Vaisseaux

Volumn 11, Issue SPEC. ISS., 1999, Pages 45-51

  Flan, Benoît ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; DRUG MANUFACTURE; DRUG PURIFICATION; FRACTIONATION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IONIC STRENGTH; PRECIPITATION; REVIEW;

EID: 0032806433     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Bergeat P. Sécurisation des médicaments dérivés du sang humain. Sang Thromb Vaiss 1998 ; 10 : 11-8.
2. Pillonel J, Saura C, Courouce AM. Dépistage des marqueurs d'une infection par le VIH et les autres virus des hépatites B et C chez les donneurs de sang en France et risque résiduel de transmission de ces virus par transfusion sanguine. Eurosurveillance 1998 ; 3 : 76-9.
3. Müller-Breitkieutz K, Evers T, Perry R Les taux des marqueurs viraux chez les donneurs de sang non rémunérés en Europe ont diminué de 1990 à 1996. Eurosurveillance 1998 ; 3 : 71-6.
4. Aubin JT, Defer C, Vidaud M, Maniez-Montreuil M, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application for the quality control of plasma for fractionation. Vox Sang (accepté pour publication).
5. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Vox Sang 1962 ; 7 : 414-24.
6. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang 1962 ; 7 : 157-74.
7. Alving BM, Hojima Y, Pisano JJ, et al. Hypotension associated with prekallikrein activator (Hageman factor fragments) in plasma protein fraction. N Engl J Med 1978 ; 299 : 66-70.
8. Hooper JA. Production and properties of intravenous immunoglobulins In : Lee ML, Strand V, eds. Intravenous immunoglobulins in clinical practice. New York : Marcel Dekker Inc., 1997.
9. Yap PL. Viral Safety of IVIG. In : Lee ML, Strand V, eds. Intravenous Immunoglobulins in clinical practice, New York : Marcel Dekker Inc., 1997.
10. Kempf C, Jentsch P, Poirier B, et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991 ; 31 : 423-7.
11. Reid KG, Cuthbertson B, Jones ADL, McIntosh RV. Potential contribution of mild pepsin treatment at PH 4 to the viral safety of human immunoglobulin products. Vox Sang 1998 ; 55 : 75-80.
12. The european agency for the evaluation of medicinal products. Note for guidance on virus validation studies : the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/ BWP/268/95.
13. Evatt B, Austin H, Banhart E, et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998 ; 38 : 817-20.
14. Sullivan MT, Schonberger LB, Kessler D, Williamns AE, Dodd RY. Creutzfeldt-Jakob disease (CJD) investigational lookback study. Transfusion 1997 ; 37 : 9S-S6.
15. Van Duijn CM, Delasnerie-Laupretre N, Masullo C, et al. Case control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993/95. Lancet 1998 ; 351 : 1081-5.
16. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996 ; 347 : 921-5.
17. The european agency for the evaluation of medicinal products. CPMP position statement on new variant CJD and plasma-derived medicinal products, London, 25 February 1998, CPMP/201/98.
18. Résumé des caractéristiques du produit TEGELINE® (31/12/97).